High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C | Zendy

Mai Abozeid | Zendy; Ayman Alsebaey | Zendy; Eman Abdelsameea | Zendy; Warda Othman | Zendy; Mostafa Elhelbawy | Zendy; Amr Rgab | Zendy; M.D. REEM A. EL-HADIDY NEVEEN M. EL-FAYOMY | Zendy; Tamer Samir Abdel-Ghafar | Zendy; Mervat Abdelkareem | Zendy; Alyaa Sabry | Zendy; Marwa Fekry | Zendy; Nashwa Shebl | Zendy; Eman Rewisha | Zendy; Imam Waked | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C

Author(s) -

Mai Abozeid,

Ayman Alsebaey,

Eman Abdelsameea,

Warda Othman,

Mostafa Elhelbawy,

Amr Rgab,

M.D. REEM A. EL-HADIDY NEVEEN M. EL-FAYOMY,

Tamer Samir Abdel-Ghafar,

Mervat Abdelkareem,

Alyaa Sabry,

Marwa Fekry,

Nashwa Shebl,

Eman Rewisha,

Imam Waked

Publication year - 2018

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2018.07.025

Subject(s) - chronic hepatitis , medicine , virology , business , virus

Direct acting antivirals (DAAs) are highly effective for treatment of hepatitis C (HCV) but brand products are priced beyond the means of most low and middle income countries (LMICs). Although a few DAAs are offered at reduced prices in access programs, they are still beyond affordability in limited resource settings with a large HCV infected population. Cheap generics might fill this economic need, but studies comparing their clinical efficacy to that of original products are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research